methocarbamol (robaxin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect. Methocarbamol is used for use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. Under the trade name Robaxin, Methocarbamol is marketed by Actient Pharmaceuticals in the United States and Pfizer in Canada.   NCATS

Chemistry

  • SMILES: COC1=CC=CC=C1OCC(O)COC(N)=O
  • InChIKey: GNXFOGHNGIVQEH-UHFFFAOYSA-N
  • Mol. Mass: 241.2405
  • ALogP: 0.53
  • ChEMBL Molecule:
    methocarbamol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0585 - $3.7808
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( methocarbamol (robaxin), acetylsalicylic acid (aspirin) )

Alternative names

delaxin | forbaxin | glycerylguaiacolate carbamate | guaiacol glyceryl ether carbamate | guaiamar carbamate | guaiphenesin carbamate | methocarbamol | méthocarbamol | methocarbamolum | metocarbamol | metocarbamolo | miolaxin | neuraxin | robaxin | robaxin-750 | (rs)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate

Organizations (76)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (64)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Musculoskeletal Pain (approved 1957)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Arthroscopy (Phase 4)

Hernia, Inguinal (Phase 4)

Hernia, Ventral (Phase 4)

Liver Cirrhosis (Phase 3)

Low Back Pain (Phase 4)

Pain (Phase 3)

Pain, Postoperative (Phase 3)

Rib Fractures (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue